A61P 19 - Drugs for skeletal disorders

Patents for A61P 19 - Drugs for skeletal disorders (81,981)
11/2006
11/02/2006	EP1717315A2 Osteoprotegerin binding proteins and receptors
11/02/2006	EP1717251A2 Methods of therapy for B-cell malignancies using human anti-CD40 antibodies
11/02/2006	EP1717230A1 Fused-ring 4-oxopyrimidine derivative
11/02/2006	EP1717229A1 Novel cyclic compound having 4-pyridylalkylthio group having (un)substituted amino introduced therein
11/02/2006	EP1717225A1 Bicyclic amide derivatives
11/02/2006	EP1717224A1 Peptidyl arginine deiminase type iv inhibitor
11/02/2006	EP1716861A2 Inhibitors of proteasomal activity for stimulating bone and hair growth
11/02/2006	EP1716851A1 Thioamides and salts thereof and cytokine production inhibitors containing both
11/02/2006	EP1715920A1 Cathepsin cysteine protease inhibitors
11/02/2006	EP1715892A2 Methods and compositions for modulating angiogenesis
11/02/2006	EP1715891A2 Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
11/02/2006	EP1715875A2 Systems and methods related to degradation of uremic toxins
11/02/2006	EP1715872A1 Improved therapy using a combination of raloxifene and alendronate
11/02/2006	EP1501565B1 Compounds and method for coating surfaces in a haemocompatible manner
11/02/2006	EP1448195B1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
11/02/2006	EP1434624B1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors
11/02/2006	EP1401801B1 Selective androgen receptor modulators and methods of use thereof
11/02/2006	EP1395568B1 4-aminopyrimidine derivatives
11/02/2006	EP1296923B1 Aspirin-triggered lipid mediators
11/02/2006	EP1250313B1 Monohydrate of cis-lithium-cyano-4- 3-(cyclopentyloxy)-4-methoxyphenyl\|cyclohexanecarboxylate
11/02/2006	EP1219596B1 Salicylamide derivatives
11/02/2006	EP1192133B1 N-cyclopentyl modulators of chemokine receptor activity
11/02/2006	EP1003721B1 Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of raf kinases
11/02/2006	CA2605796A1 Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
11/02/2006	CA2605594A1 Heterocyclic compound
11/02/2006	CA2605365A1 Remedy for xanthoma
11/02/2006	CA2605331A1 Calcium bis[(2s)-3-[3-[(2s)-3-(4-chloro-2-cyanophenoxy)-2- fluoropropoxy]phenyl]-2-isopropoxypropionate] and intermediate thereof
11/02/2006	CA2604454A1 Artificial cerebrospinal fluid
11/01/2006	CN1856478A Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
11/01/2006	CN1856321A Use of calcitonin in osteoarthritis
11/01/2006	CN1856319A Agent for promoting osteogenesis and/or inhibiting bone resorption
11/01/2006	CN1856301A Curable beta-amino acid
11/01/2006	CN1853691A Oral liquid for treating cervix severe bone injury
11/01/2006	CN1853680A Medicinal composition for treating cervical spondylosis and preparation thereof
11/01/2006	CN1853679A Medicinal composition for treating cervical spondylosis and preparation thereof
11/01/2006	CN1853664A Medicinal composition for treating wound and preparation thereof
11/01/2006	CN1853653A Composition containing pearl and vitamine and its use
11/01/2006	CN1282636C Vitamin D analogues
10/2006
10/31/2006	US7129356 Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
10/31/2006	US7129270 Antiinflammatory agents
10/31/2006	US7129258 Substituted benzoxazoles as estrogenic agents
10/31/2006	US7129253 Compounds
10/31/2006	US7129246 N-adamantlmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation
10/31/2006	US7129243 Respiratory system disorders; cardiovascular disorders; antidiabetic agents; antiarthritic agents; antiinflammatory agents; immunosuppressants
10/31/2006	US7129242 Such as 4-((4-chlorophenyl)pyrimidin-2-yl)amino)benzamide; for treatment of inflammation/autoimmune conditions
10/31/2006	US7129241 Pyridazine derivatives
10/31/2006	US7129236 For therapy of immune related responses, tumor growth, glomerulonephritis, inflammation, malarial anemia, septic shock, tumor associated angiogenesis, vitreoretinopathy, psoriasis, graft versus host disease, atopic dermatitis
10/31/2006	US7129225 Administering an effective amount of a protein tyrosine kinase inhibitor (containing first and second module) to the patient to protect against or to treat hearing loss
10/31/2006	US7129219 enhance humoral and cell-mediated immune responses to vaccine antigens; 2-deoxy-2-amino- beta -D-glucopyranose (glucosamine) glycosidically linked to an cyclic aminoalkyl (aglycon) group
10/31/2006	US7129064 Canine hepatocyte growth factor
10/31/2006	US7128911 Virus-like particle, and an antigen or antigenic determinant of a receptor activator factor kappa beta ligand protein, fragment or peptide
10/31/2006	CA2355886C Substituted oximes and hydrazones as neurokinin antagonists
10/31/2006	CA2262906C Novel immunotherapeutic agents and their use in the reduction of cytokine levels
10/26/2006	WO2006113942A2 Method of inhibiting cathepsin activity
10/26/2006	WO2006112889A1 Dosage forms of risedronate
10/26/2006	WO2006112442A1 Benzimidazole compound
10/26/2006	WO2006112331A1 Novel condensed pyrrole derivative
10/26/2006	WO2006112012A1 Nutrient composition
10/26/2006	WO2006111720A2 Use
10/26/2006	WO2005102301A3 Hydroxymethylbutyrate compositions and uses thereof
10/26/2006	WO2002100445A8 Treatment and composition for wound healing
10/26/2006	US20060241171 Novel physiologically active substances
10/26/2006	US20060241169 Crystalline forms of [R-(R.R)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)
10/26/2006	US20060241132 Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient
10/26/2006	US20060241126 Phospholipase inhibitors perticularly phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2; N-(1-Methylpiperidin-4-yl)-(2-(2-(2,3-difluorophenyl)ethyl)-4-oxo-4H-pyrido[2,3-d]pyrimidin-1-yl)-N-(4-(4-trifluoromethylphenyl)phenyl)methylacetamide; amidation
10/26/2006	US20060241116 affinity for peripheral-type benzodiazepine receptors; in vitro and in vivo affinity; chemical intermediates
10/26/2006	US20060241112 Kinase inhibitors
10/26/2006	US20060241087 Phosphonates useful as modulators of t $g(g)9$g(d)2 lymphocyte activity
10/26/2006	US20060241066 Decoy composition for treating and preventing inflammatory disease
10/26/2006	US20060240520 monitoring the efficacy of a BAFF-R (a B-cell activating factor belonging to the Tumor Necrosis Factor family) antagonist in the treatment of a disease or disorder associated with aberrant levels of B-cells or B-cell activity
10/26/2006	US20060240519 Novel receptor nucleic acids and polypeptides
10/26/2006	US20060240518 polypeptides related to a receptor to BAFF (a B-cell activating factor belonging to the Tumor Necrosis Factor family, which is associated with theexpression of B-cells and immunoglobulins); this receptor can be employed in the treatment of cancers, lymphomas, autoimmune diseases related to B-cells
10/26/2006	US20060240517 Novel receptor nucleic acids and polypeptides
10/26/2006	US20060240094 Masticatable capsule and process for producing the same
10/26/2006	US20060240023 Apoptosis-associated protein and use thereof
10/26/2006	US20060240012 For treating inflammation and immunopathy; rheumatoid arthritis
10/26/2006	US20060240010 Methods of modulating CD200 receptors
10/26/2006	US20060240004 Methods for treating tweak-related conditions
10/26/2006	DE102005018887A1 Topical pain therapy, useful to treat pain of calcified fascia and tendons, comprises using topical formulation containing decalcified phosphocitrate, injecting into calcium deposits and working effectively at place of application
10/26/2006	CA2675652A1 Dosage forms of risedronate
10/26/2006	CA2603518A1 Nutrient composition for promoting collagen production
10/26/2006	CA2602610A1 Benzimidazole compound
10/26/2006	CA2602022A1 Binding immunoglobulin protein (bip) for prevention or treatment of bone conditions or diseases
10/25/2006	EP1715038A1 Antibody targeting osteoclast-associated protein
10/25/2006	EP1714977A2 Synthesis of cyclosporin analogs
10/25/2006	EP1714969A2 Immunostimulatory nucleic acid molecules
10/25/2006	EP1714656A1 Ed-71 preparation
10/25/2006	EP1714648A1 Combination drug
10/25/2006	EP1714646A1 Pharmaceutical composition containing bakuchiol for treating osteoporosis in women
10/25/2006	EP1714645A1 Pharmaceutical composition containing bakuchiol for treating breast cancer in women
10/25/2006	EP1713815A1 Pth agonists
10/25/2006	EP1713772A1 Novel piperidines as chemokine modulators (ccr)
10/25/2006	EP1713489A2 Solid and crystalline ibandronate sodium and processes for preparation thereof
10/25/2006	EP1713481A2 Novel uses for proton pump inhibitors
10/25/2006	EP1713464A2 Glycine and/or proline for use in cartilage affecting conditions
10/25/2006	EP1713463A2 Reelin deficiency or dysfunction and methods related thereto
10/25/2006	EP1517909B1 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
10/25/2006	EP1458718B1 Quinolinones as prostaglandin receptor ligands
10/25/2006	EP1430053B1 AZAOXOINDOLE DERIVATIVES AS Trk PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND CHRONIC PAIN
10/25/2006	EP1383511B1 Calcilytic compounds

1 ... 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 ... 820